Pangea Bio Accepted to One Mind Accelerator Program

Pangea Bio Accepted to One Mind Accelerator Program

Pangea Announces Upcoming Abstract Presentation at AD/PD 2024 Conference in Lisbon

Pangea Announces Upcoming Abstract Presentation at AD/PD 2024 Conference in Lisbon

Pangea Bio Accepted to Join Einstein Biotech Innovation Program

Pangea Bio Accepted to Join Einstein Biotech Innovation Program

Kanna Health announces FDA and MHRA approvals to begin its Phase 1 clinical trial

Kanna Health announces FDA and MHRA approvals to begin its Phase 1 clinical trial

Kanna Health announces FDA and MHRA approvals to begin its Phase 1 clinical trial for the development of KH-001 as first FDA-approved treatment for premature ejaculation

Kanna Health announces patent application publication for novel synthetic mesembrine-inspired alkaloids as treatments for neurology, psychiatric, and inflammation-related diseases

Kanna Health announces patent application publication for novel synthetic mesembrine-inspired alkaloids as treatments for neurology, psychiatric, and inflammation-related diseases

People | Product | Potential Special Edition on the World’s Indigenous People International Day

People | Product | Potential Special Edition on the World’s Indigenous People International Day

Kanna Health announces patent application publication for KH-001 as premature ejaculation treatment

Kanna Health announces patent application publication for KH-001 as premature ejaculation treatment